Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MGD024

Phase 1Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Leukemia Acute MyeloidActive, not recruiting

Leukemia Acute MyeloidPhase 1

Active, not recruiting

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Leukemia Acute Myeloid

NCT05362773

Clinical

Trials by Indication[1]

Leukemia Acute Myeloid1 trial

A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies

Active, not recruiting·MMacroGenics·Phase 1·NCT05362773·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MGD024. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MGD024 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MGD024. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MacroGenics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMacroGenics

Related News